Showcasing A Novel CD47-Targeted Protein Drug Conjugate with Broad Anti-Tumor Activity in Diverse Models

• Engineering a CD47 ligand as a selective tumor-targeting moiety
• Demonstrating potent in vitro and in vivo efficacy of KBA651 across diverse cancer models
• Evaluating pharmacokinetics and safety to support translational studies

Speakers:

Joe nabhan

cso

K2B Therapeutics Inc.